Target Price | $663.00 |
Price | $425.45 |
Potential | 55.84% |
Number of Estimates | 24 |
24 Analysts have issued a price target Synopsys 2026 . The average Synopsys target price is $663.00. This is 55.84% higher than the current stock price. The highest price target is $750.75 76.46% , the lowest is $553.94 30.20% . | |
A rating was issued by 28 analysts: 25 Analysts recommend Synopsys to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Synopsys stock has an average upside potential 2026 of 55.84% . Most analysts recommend the Synopsys stock at Purchase. |
26 Analysts have issued a sales forecast Synopsys 2025 . The average Synopsys sales estimate is $7.0b . This is 13.21% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $7.9b 23.20% , the lowest is $6.6b 2.25% .
This results in the following potential growth metrics:
2024 | $6.1b | 15.22% |
---|---|---|
2025 | $7.0b | 14.94% |
2026 | $8.4b | 18.70% |
2027 | $9.5b | 14.08% |
2028 | $13.3b | 39.71% |
2029 | $15.5b | 16.09% |
2030 | $17.3b | 11.92% |
2031 | $19.4b | 11.82% |
18 Analysts have issued an Synopsys EBITDA forecast 2025. The average Synopsys EBITDA estimate is $2.9b . This is 123.88% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.2b 182.54% , the lowest is $2.8b 140.70% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $1.4b | 2.72% |
---|---|---|
2025 | $2.9b | 114.66% |
2026 | $3.6b | 20.65% |
2027 | $4.1b | 16.72% |
2024 | 22.39% | 10.85% |
---|---|---|
2025 | 41.81% | 86.73% |
2026 | 42.50% | 1.65% |
2027 | 43.48% | 2.31% |
26 Synopsys Analysts have issued a net profit forecast 2025. The average Synopsys net profit estimate is $2.4b . This is 9.82% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 23.55% , the lowest is $2.1b 4.28% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 84.03% |
---|---|---|
2025 | $2.4b | 4.96% |
2026 | $2.6b | 11.36% |
2027 | $3.1b | 17.86% |
2028 | $3.9b | 26.02% |
2024 | 36.94% | 59.72% |
---|---|---|
2025 | 33.73% | 8.69% |
2026 | 31.64% | 6.20% |
2027 | 32.69% | 3.32% |
2028 | 29.49% | 9.79% |
26 Analysts have issued a Synopsys forecast for earnings per share. The average Synopsys EPS is $15.31 . This is 10.54% higher than earnings per share in the financial year 2024. The highest EPS forecast is $15.91 28.83% , the lowest is $13.43 8.74% .
This results in the following potential growth metrics and future valuations:
2024 | $14.51 | 83.21% |
---|---|---|
2025 | $15.31 | 5.51% |
2026 | $17.05 | 11.37% |
2027 | $20.10 | 17.89% |
2028 | $25.33 | 26.02% |
Current | 30.72 | 36.51% |
---|---|---|
2025 | 27.79 | 9.53% |
2026 | 24.95 | 10.22% |
2027 | 21.17 | 15.15% |
2028 | 16.80 | 20.64% |
Based on analysts' sales estimates for 2025, the Synopsys stock is valued at an EV/Sales of 10.62 and an P/S ratio of 11.22 .
This results in the following potential growth metrics and future valuations:
Current | 12.03 | 5.71% |
---|---|---|
2025 | 10.62 | 11.70% |
2026 | 8.95 | 15.75% |
2027 | 7.84 | 12.34% |
2028 | 5.61 | 28.42% |
2029 | 4.84 | 13.86% |
2030 | 4.32 | 10.65% |
2031 | 3.86 | 10.57% |
Current | 12.70 | 8.55% |
---|---|---|
2025 | 11.22 | 11.67% |
2026 | 9.45 | 15.75% |
2027 | 8.29 | 12.34% |
2028 | 5.93 | 28.42% |
2029 | 5.11 | 13.86% |
2030 | 4.56 | 10.65% |
2031 | 4.08 | 10.57% |
Analyst | Rating | Action | Date |
---|---|---|---|
Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Sep 11 2025 |
Mizuho |
Outperform
➜
Outperform
|
Unchanged | Sep 11 2025 |
Keybanc |
Overweight
➜
Overweight
|
Unchanged | Sep 10 2025 |
B of A Securities |
Buy
➜
Underperform
|
Downgrade | Sep 10 2025 |
Goldman Sachs |
Buy
➜
Buy
|
Unchanged | Sep 10 2025 |
Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Sep 10 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Sep 10 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Sep 11 2025 |
Unchanged
Mizuho:
Outperform
➜
Outperform
|
Sep 11 2025 |
Unchanged
Keybanc:
Overweight
➜
Overweight
|
Sep 10 2025 |
Downgrade
B of A Securities:
Buy
➜
Underperform
|
Sep 10 2025 |
Unchanged
Goldman Sachs:
Buy
➜
Buy
|
Sep 10 2025 |
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Sep 10 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Sep 10 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.